CO.DON finally saved

Investor has taken over the business operations of the biopharmacy company

27-Jan-2023 - With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a company of the American-Chinese ReLive Group, concluded in October 2022 as a result ...

CO.DON negotiates with Xintela on the establishment of a joint venture

10-Jul-2018 - CO.DON AG has signed a letter of intent (LOI) with Xintela AB, Lund (Sweden), by which the two companies have agreed to start negotiations regarding the establishment of a joint venture for the development and commercialization of stem cell based options for the treatment of cartilage disorders, ...

co.don AG in list of Growth Champions for 2016

7th place in the category Chemicals and Pharma

07-Dec-2015 - The news magazine "Focus" has included co.don AG in its list of Growth Champions for 2016, which is published in the Focus Spezial issue. Growth Champions 2016 presents the list of the 500 fastest growing companies in Germany, classified by industry and defined by their average revenue growth. ...

co.don AG is awarded the US-Patent: Process to produce cell transplants patented successfully

15-Mar-2011 - co.don AG has announced yet another great achievement. An important patent has been granted recently to the Brandenburg enterprise by the American patent office "United States Patent and Trademark Office". The refined method by co.don AG for growing three-dimensional autologous cell transplants ...

co.don AG signs an exclusive distribution agreement for Greece

05-Jan-2007 - co.don® AG has signed an exclusive two-year distribution agreement with ARTHROSIS SA, Metamorfosi, near Athens, Greece, - to market co.don chondrosphere® , co.don chondrotransplant® DISC and co.don osteotransplant® DENT in Greece. ARTHROSIS SA is an established distribution company which has ...